The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review
Filippo Biondi1, Rosalinda Madonna1
1Department of Pathology, Cardiology Division, University of Pisa, Via Paradisa, 56124 Pisa, Italy.
Journal of Clinical Medicine
|April 26, 2025
Summary
Glucagon-like peptide-1 receptor agonists (GLP1-RAs) show cardioprotective effects against chemotherapy-induced cardiotoxicity. While evidence is limited, studies suggest GLP1-RAs mitigate cardiovascular damage via pathways like oxidative stress and inflammation.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are key in type 2 diabetes mellitus (T2DM) and cardiovascular disease management.
- Cardiotoxicity, a severe side effect of anti-cancer treatments, lacks effective preventive options.
- GLP1-RAs exhibit cardioprotective properties by targeting pathways like oxidative stress and inflammation.
Purpose of the Study:
- To review and analyze research on GLP1-RAs for preventing or mitigating anti-cancer treatment-related cardiotoxicity.
- To map the scope and characteristics of existing studies in this field.
Main Methods:
- A scoping review adhering to PRISMA guidelines.
- Included thirteen studies identified through a comprehensive search string combining GLP1-RA and cardiotoxicity terms.
- Studies comprised clinical registry data, animal models, and cell cultures.
Main Results:
- Most studies indicated a cardioprotective effect of GLP1-RAs.
- Identified mechanisms include modulation of NF-κB, IL-6, reactive oxygen species, and caspase-3.
- Study designs and quality varied, with limited clinical evidence.
Conclusions:
- Existing evidence suggests GLP1-RAs may protect against cardiotoxicity, despite limitations in study quantity and standardization.
- Further clinical research is essential to confirm these cardioprotective effects and establish clinical utility.
- GLP1-RAs represent a promising therapeutic avenue for managing chemotherapy-induced cardiotoxicity.
Keywords:
GLP1-RAHER2anti-cancer treatmentantrhacyclinescardioncologychemotherapydulaglutideexenatideglucagon-like peptide-1 receptor agonistsliraglutidesemaglutidetirzepatideMore Related Videos
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
1.7K
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
11.5K
Related Concept Videos
01:24Glucagon-like Receptor Agonists
261
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
261
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
136
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
136
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
109
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
109
01:26Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K